TP53 and ovarian serous adenocarcinoma: The therapeutic potential of APR-246 extends beyond hematologic malignancies, as demonstrated in a phase Ib/II trial (NCT02098343) involving patients with platinum-sensitive, TP53-mutated high-grade serous ovarian cancer.